Avatrombopag/Suxin is safe and effective in children with immune thrombocytopenia

Avatrombopag is an effective and safe oral therapy for pediatric patients with immune thrombocytopenia (ITP), according to a published study. The results of this study provide an important reference for medical practice in this field and also bring new hope to pediatric patients suffering from this condition.

Avatrombopag is an oral thrombophilia receptor agonist currently approved for the treatment of adult patients with chronic ITP who have had an inadequate response to prior therapy. ITP is an autoimmune disease in which a patient's immune system mistakenly attacks and destroys platelets, resulting in a low platelet count and an increased risk of bleeding. Treatment of ITP is more complex for pediatric patients because their physical and psychological states are different from adults and may respond differently to medications. Therefore, it is crucial to find a safe and effective treatment option.

In this study, researchers conducted two real-world observational studies and showed that avatrombopag was equally effective and well-tolerated in the pediatric population, laying the foundation for further clinical application. The researchers are particularly concerned about the effectiveness and safety of avatrombopag in treating ITP in children, which needs to be verified through rigorous clinical trials.

Investigators reported results from the AVA-PED-301 study, a 12-week Phase 3b trial that included an (ongoing) open-label expansion phase. The purpose of this trial was to evaluate the use of avatrombopag in children with ITP. The study was conducted at 62 sites in Asia and Europe, covering pediatric patients from different regions, ensuring the broad applicability of the findings.

A total of 75 pediatric patients were included in this study, 54 of whom received avatrombopag and 21 received placebo. The researchers conducted a detailed comparison of the treatment effects of the two groups of patients and found that avatrombopag was superior to placebo in many aspects. For example, 28% of patients with avatrombopag had a durable platelet response (i.e., platelet count ≥50 × 10⁹ cells/L) and achieved target counts for at least 6 of 8 weeks during the second half of the core phase of treatment, compared with 0% of patients in the placebo group. This result demonstrates that avatrombopag has a significant clinical advantage in increasing platelet counts.

Avatrombopag's efficacy varied across age cohorts. In the first cohort, the proportion of patients who received avatrombopag achieved a durable platelet response43%; in the second cohort it was 20%; and in the third cohort it was 15%. This data suggests that the efficacy of avatrombopag may vary with age, providing new directions for future research.

In addition, 81% of patients in the avatrombopag group had at least 2 consecutive platelet counts of 50 × 10⁹ cells/L or higher during the core phase of treatment; compared with 0% of patients in the placebo group, this goal was achieved. This further confirms the effectiveness of avatrombopag in increasing platelet counts. In addition, a total of 56% of patients in the avatrombopag group achieved a platelet response during treatment without the need for rescue therapy, whereas no patients in the placebo group achieved this success.

In terms of safety, the safety profile of avatrombopag in this study was consistent with that in adult patients with chronicITP, indicating that its use in pediatric patients is safe. The study results show that avatrombopag has relatively mild side effects and is well tolerated by patients, which is undoubtedly a major benefit for families hoping to obtain long-term treatment effects.

References:https://www.hematologyadvisor.com/news/avatrombopag-safe-effective-pediatric-patients-immune-thrombocytopenia/